Key Points
- Zai Lab CEO Ying Du sold 50,000 shares on May 14 at an average price of $20.09, generating about $1.0 million in proceeds. After the sale, Du still held 1,122,626 shares, down 4.26% from before the transaction.
- The article notes additional recent insider sales by Du in early April, including 2,653 shares on April 6 and 5,576 shares on April 2.
- Zai Lab’s stock was trading around $20.59, near its 50-day and 200-day moving averages, while analysts currently have a consensus rating of “Moderate Buy” with an average target price of $45.83.
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 50,000 shares of the company's stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $20.09, for a total value of $1,004,500.00. Following the completion of the sale, the chief executive officer owned 1,122,626 shares in the company, valued at approximately $22,553,556.34. This represents a 4.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Ying Du also recently made the following trade(s):
- On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The stock was sold at an average price of $20.45, for a total value of $54,253.85.
- On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total value of $113,694.64.
Zai Lab Trading Up 1.3%
Zai Lab stock opened at $20.59 on Friday. Zai Lab Limited Unsponsored ADR has a 12 month low of $15.96 and a 12 month high of $44.34. The stock's 50 day simple moving average is $20.34 and its two-hundred day simple moving average is $19.82. The firm has a market cap of $2.34 billion, a PE ratio of -12.71 and a beta of 0.85.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The company had revenue of $99.61 million during the quarter. On average, equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.22 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,396 shares of the company's stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC's holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. Institutional investors own 41.65% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on ZLAB shares. Wall Street Zen lowered Zai Lab from a "hold" rating to a "sell" rating in a research report on Saturday. Zacks Research lowered Zai Lab from a "hold" rating to a "strong sell" rating in a research report on Friday, January 23rd. Cantor Fitzgerald decreased their target price on Zai Lab from $55.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, February 27th. Citigroup decreased their target price on Zai Lab from $47.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 8th. Finally, Jefferies Financial Group upgraded Zai Lab to a "strong-buy" rating in a research report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.83.
Get Our Latest Stock Analysis on Zai Lab
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
